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Abstract
Background: Estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) are renal
markers associated with risks of cardiovascular diseases (CVD) and all-cause mortality in diabetic patients. This study
aims to quantify such risks in Chinese diabetic patients based on eGFR and UACR.
Methods: This was a territory-wide retrospective cohort study on primary care diabetic patients with documented
eGFR and UACR but without baseline CVD in 2008/2009. They were followed up till 2013 on CVD events and
mortality. Associations between eGFR/UACR and incidence of CVD/mortality were evaluated by multivariable Cox
proportional models adjusted with socio-demographic and clinical characteristics.
Results: The data of 66,311 patients who had valid baseline eGFR and UACR values were analysed. The risks of CVD
events and mortality increased exponentially with the decrease in eGFR, with a hazard ratio (HR) increasing from 1.63
to 4.55 for CVD, and from 1.70 to 9.49 for mortality, associated with Stage 3 to 5 CKD, compared to Stage 1 CKD. UACR
showed a positive linear association with CVD events and mortality. Microalbuminuria was associated with a
HR of 1.58 and 2.08 for CVD and mortality in male (1.48 and 1.79 for female), respectively, compared to no
microalbuminuria. Male patients with UACR 1–1.4 mg/mmol and eGFR ≥90 ml/min/1.73 m2 (60–89 ml/min/1.
73 m2) had a HR of 1.25 (1.43) for CVD. Female patients with UACR 2.5–3.4 mg/ml and eGFR ≥90 ml/min/1.
73 m2 (60–89 ml/min/1.73 m2) had a HR of 1.45 (1.65) for CVD.
Conclusions: Risks of CVD events and mortality increased exponentially with eGFR drop, while UACR showed positive
predictive linear relationships, and the risks started even in high-normal albuminuria. UACR-based HR was further
modified according to eGFR level, with risk progressed with CKD stage. Combining eGFR and UACR level was more
accurate in predicting risk of CVD/mortality. The findings call for more aggressive screening and intervention of
microalbuminuria in diabetic patients.
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Background
Chronic kidney disease is one of the major complica-
tions in patients with Type 2 Diabetes Mellitus (T2DM).
Renal impairment in diabetic patients can be manifested
as a decrease in the estimated glomerular filtration rate
(eGFR), the progression from microalbuminuria to
macroalbuminuria to proteinuria, or both. Despite diabetic
nephropathy is typically characterized by albuminuria (as
commonly assessed by urine albumin-to-creatinine ratio,
UACR), previous studies showed that albuminuria may be
absent in some diabetic patients with an abnormal eGFR.
Both low eGFR level and albuminuria had been shown to
be independent poor prognostic factors for patients with
diabetes [1–9]. UACR and eGFR were two commonly used
indicators to assess renal function, and were found to be
associated with cardiovascular and all-cause mortality [10].
There were studies trying to explore the relationship be-
tween eGFR and albuminuria on the prognosis of patients
with diabetes mellitus (DM). A strong synergistic inter-
action between eGFR and albuminuria was found, in
addition to the independent association of these parame-
ters with mortality and progression to end-stage renal dis-
ease [11]. Studies in non-Chinese population had shown
that eGFR and albuminuria were predictors of cardiovascu-
lar diseases (CVD) and mortality [1, 12–14]. However,
there was limited information on whether eGFR and
UACR have similar predictive values, if any, on CVD and
mortality in Chinese patients with Type 2 DM, and the re-
lationship between UACR and eGFR on clinical outcomes.
This study aims to explore the association between
eGFR with both the risks of CVD events and all-cause
mortality, and the risk modification by co-existing
albuminuria. The association of albuminuria and CVD
events and all-cause mortality would be quantified. The
association between different levels of eGFR and albu-
minuria with risks of CVD events and all-cause mortal-
ity in patients with T2DM would also be identified.
Study objectives are to: [1] explore the relationship
between eGFR and risks of CVD and all-cause mortal-
ity. [2] quantify the association between albuminuria
and risks of CVD and all-cause mortality. [3] reveal the
association between eGFR and albuminuria through
identifying different hazard ratios (HR) on CVD events
and all-cause mortality of patients with T2DM based on
different levels of eGFR and albuminuria.
Methods
Study design
This is a territory-wide retrospective cohort study with
Chinese subjects aged between 18 and 79. All subjects
were clinically diagnosed with T2DM, with no prior
CVD event and had DM management in one of the 74
General Out-Patient Clinics of the Hong Kong Hospital
Authority (HA) across the whole territory. HA is the
centralized organization that governs all public-sector
hospitals and primary care clinics in Hong Kong and
manages over half of all diabetic patients under primary
care. Clinical data from 1 August 2008 to 31 December
2009 were collected from a territory-wide study for the
evaluation of local diabetic programmes [15]. Through
the administrative database of HA, clinical diagnosis of
T2DM was identified by the International Classification
of Primary Care-2 (ICPC-2) code of ‘T90’. Each patient
was observed from their earliest record of eGFR/UACR,
as the baseline date, to the following events whichever
came first: the date of incidence of outcome event or all-
cause mortality, or the last follow-up as censoring until
31 December 2013.
Definitions
The Kidney Disease: Improving Global Outcomes (KDIGO)
organization developed clinical practice guidelines in 2012
[16, 17] in which GFR Category 1 (or CKD Stage 1) was
defined as eGFR ≥90 ml/min/1.73 m2, GFR Category 2 (or
CKD Stage 2) as eGFR 60–89 ml/min/1.73 m2, Category
G3 (including G3a and G3b, or CKD Stage 3) as eGFR 30–
59 ml/min/1.73 m2, Category G4 (or CKD Stage 4) as eGFR
<30 ml/min/1.73 m2, and GFR G5 (or CKD stage 5) as
eGFR <15 ml/min/1.73 m2. The KDIGO also had a defin-
ition on albuminuria with A1 (normal to mildly increased)
as ACR < 30 mg/g (or < 3 mg/mmol), A2 (moderately in-
creased) as ACR 30–300 mg/g (or 3–30 mg/mmol), and
A3 (severely increased) as > 300 mg/g (or > 30 mg/mmol).
We adopted the definition of microalbuminuria and dia-
betic nephropathy in the local Hong Kong Reference
Framework for Diabetes Care for Adults in Primary Care
Settings, in which microalbuminuria was defined as
UACR > 2.5 mg/mmol in men and > 3.5 mg/mmol in
women, and UACR > 25 mg/mmol as diabetic nephropathy
(or macroalbuminuria) [18].
Cardiovascular diseases and mortality identification
Outcomes of interest included three events: 1) CVD event
with one of the following subtype diagnoses: coronary
heart disease (CHD), stroke, or heart failure, 2) all-cause
mortality and 3) composite of CVD and all-cause mortal-
ity. Diagnosis of comorbidities was identified with the
diagnosis coding system of ICPC-2 and International
Classification of Diseases, Ninth Edition, Clinical Modifi-
cation (ICD-9-CM). CHD including ischaemic heart dis-
ease, myocardial infarction, coronary death and sudden
death was taken as ICPC-2 of K74 to K76 or ICD-9-CM
of 410.x, 411.x to 414.x, 798.x. Heart failure was taken as
ICPC-2 of K77 or ICD-9-CM of 428.x. Stroke including
fatal and non-fatal was taken as ICPC-2 of K89 to K91 or
ICD-9-CM of 430.x to 438.x.
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Baseline eGFR, UACR and other measurements
Clinical baseline eGFR and UACR readings in the pa-
tient records were extracted for analysis. The eGFR was
calculated based on the creatinine level from blood test
according to the abbreviated Modification of Diet in
Renal Disease Study formula recalibrated for Chinese
(eGFR in ml/min/1.73 m2 = 186 × [(serum creatinine in
μmol/L) × 0.011] -1.154 × (age)-0.203 × (0.742 if female) ×
1.233, where 1.233 is the adjusted coefficient for Chinese
[19]. Urine ACR was estimated based on spot urine sam-
ple for albumin to creatinine ratio. Baseline covariates
included socio-demographics, clinical parameters, dis-
ease characteristics and treatment modalities of patients.
Socio-demographics consisted of gender, age, smoking
status and drinking habit. Clinical parameters were
Haemoglobin A1c (HbA1c), body mass index (BMI),
waist-to-hip ratio (WHR), systolic blood pressure (SBP),
diastolic blood pressure (DBP), lipid profile (Low-density
lipoprotein-cholesterol (LDL-C) and total cholesterol to
high-density lipoprotein cholesterol ratio (TC/HDL-C
ratio)) and triglyceride (TG). Disease characteristics
composed of self-reported family history of DM, diag-
nosed hypertension and duration of DM. Hypertension
was defined as clinical diagnosis with ICPC-2 code of
“K86” or “K87”. Treatment modalities composed of usage
of anti-hypertensive drug(s), oral anti-diabetic drug(s), in-
sulin and lipid-lowering agent(s). All laboratory assays
were performed in accredited laboratories by the College
of American Pathologists of the Hong Kong Accreditation
Service or the National Association of Testing Authorities
in Australia.
Data analysis
Missing data was handled by multiple imputation [20].
Each missing value was imputed five times by the
chained equation method, equivalent to attain a relative
efficiency of 95% [21, 22]. For each of the five imputed
datasets, the same analysis was performed and the five
sets of results were combined using Rubin’s rules [21].
All subjects were categorized in the following three
ways: 1) as one of the five groups according to baseline
eGFR value (≥90 ml/min/1.73 m2, 60–89 ml/min/
1.73 m2, 30–59 ml/min/1.73 m2, 15–29 ml/min/
1.73 m2 and <15 ml/min/1.73 m2); 2) as one of the
eleven groups according to baseline UACR value
(<0.5 mg/mmol, 0.5–0.9 mg/mmol, 1–1.4 mg/mmol,
1.5–1.9 mg/mmol, 2–2.4 mg/mmol, 2.5–3.4 mg/mmol,
3.5–4.9 mg/mmol, 5–9.9 mg/mmol, 10–24.9 mg/mmol,
25–34.9 mg/mmol and ≥35 mg/mmol); 3) as one of the
21 combinations of eGFR (≥90 ml/min/1.73 m2, 60–
89 ml/min/1.73 m2 and <60 ml/min/1.73 m2) and UACR
(<1 mg/mmol, 1–1.4 mg/mmol, 1.5–2.4 mg/mmol, 2.5–
3.4 mg/mmol, 3.5–24.9 mg/mmol, 25–34.9 mg/mmol and
≥35 mg/mmol). All UACR groups were further stratified
according to gender. Descriptive statistics were shown
after multiple imputation for each subgroup of eGFR
and UACR.
Differences in baseline characteristics between groups
were assessed using ANOVA for continuous variables or
chi-square test for categorical variables. Incidence rate
was estimated by an exact 95% confidence interval (CI)
based on a Poisson distribution [23]. Differences in inci-
dences of CVD, all-cause mortality and composite of
CVD and all-cause mortality between groups were tested
by log-rank tests. The eGFR and UACR groups associ-
ated with incidences of CVD, all-cause mortality and
composite of CVD and all-cause mortality were exam-
ined using multivariable Cox proportional hazards re-
gressions, with adjustment of all baseline covariates. The
interaction term between eGFR and UACR as the con-
tinuous variables was also tested. Proportional hazards
assumption was checked by examining plots of the
scaled Schoenfeld residuals against time for the covari-
ates and the presence of multi-collinearity was assessed
through variance inflation factor.
All significance tests were two-tailed and those with a
p-value less than 0.05 were considered statistically sig-
nificant. Statistical analysis was performed using STATA
Version 13.0.
Results
A total of 160,609 Chinese subjects with T2DM, eGFR
or UACR measurements, aged ≥18, received their DM
care in primary care clinics of HA from 1 August 2008
to 31 December 2010. With the exclusion of 13,457 pa-
tients with prior CVD event and 199 patients without
follow-up after baseline, the remaining 146,953, 67,334
and 66,311 patients with valid record of eGFR, UACR
and both, respectively, were included for analysis. Data
completion rates for baseline factors were over 80%.
Table 1 displays the baseline characteristics for each
eGFR group after multiple imputation. Relative to the
lower eGFR groups, higher eGFR groups had 1) lower
HbA1c, BMI, DBP and LDL-C; 2) a relatively longer
duration of DM; and 3) a larger proportion of usage of
insulin.
Tables 2, 3 and 4 and Fig. 1 show the number, un-
adjusted incidence rates, and adjusted HR of the three
outcome events for each eGFR and UACR group.
During a median follow-up period of 14.5–51.5 months,
incidence rates of composite of CVD and all-cause mor-
tality were between 22.1 and 401.3 per 1,000 person-
years among all eGFR groups. Similarly, incidence rate
of composite of CVD and all-cause mortality were be-
tween 12.4 and 65.5 per 1,000 person-years among all
UACR groups during a median follow-up period of
41.5–47.5 months for female; and between 16.1 and 79.5
per 1,000 person-years during a median follow-up period
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of 41.5–46.5 months for male. The risks of CVD events
and mortality increased exponentially with the decrease
in eGFR, with HR raised from 1.63 to 4.55 (from CKD
Stage 3 to 5) for CVD and from 1.70 to 9.49 (from CKD
Stage 3 to 5) for all-cause mortality, compared with
CKD Stage 1. Urine ACR showed a positive linear asso-
ciation with CVD and mortality. Microalbuminuria had
HR of 1.58 (male) and 1.48 (female) for CVD; and 2.08
(male) and 1.79 (female) for mortality. HR rose to 2.57
and 4.36 respectively for male, and 2.40 and 3.07 re-
spectively for female, if progressed to frank albuminuria.
The adjusted HR of CVD, all-cause mortality and
composite of CVD and all-cause mortality of different
combinations of eGFR and UACR are summarized in
Fig. 2. Male patients with UACR 1–1.4 mg/mmol and
eGFR ≥90 ml/min/1.73 m2 (60–89 ml/min/1.73 m2) had
Fig. 1 Adjusted hazard ratios for incidence of cardiovasular diseases (CVD), all-cause mortality and composite of CVD and mortality by updated
mean (a) estimated glomerular filtration rate (eGFR) and (b) urine albumin/creatinine (UACR) ratio by multivariable Cox proportional
hazards regression
Fig. 2 Adjusted hazard ratios for incidence of a cardiovasular diseases, b all-cause mortality and c a composite of cardiovasular diseases and all-
cause mortality by updated estimated glomerular filtration rate (eGFR) and urine albumin/creatinine ratio (UACR) compared to the reference
group with eGFR 90–104 ml/min/1.73 m2 and UACR 0–0.9 mg/mmol. Hazard ratios were adjusted for age, gender, smoking status, drinking habit,
body mass index, waist-to-hip ratio, glycated hemoglobin A1c, systolic and diastolic blood pressure, low-density lipoprotein-cholesterol, total
cholesterol to high-density lipoprotein cholesterol ratio, triglyceride, self-reported duration of diabetes mellitus, family history of diabetes mellitus,
diagnosed hypertension, the usage of anti-hypertensive drugs, oral anti-diabetic drugs, insulin and lipid-lowering agents at baseline
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a HR of 1.25 (1.43) for CVD. Male patients with UACR
1.5–2.4 mg/mmol and eGFR ≥90 ml/min/1.73 m2 (60–
89 ml/min/1.73 m2) had a HR of 1.54 (1.56) for all-cause
mortality, which raised further to 2.51 if eGFR was
<60 ml/min/1.73 m2. Female patients with UACR
2.5–3.4 mg/ml and eGFR ≥90 ml/min/1.73 m2 (60–
89 ml/min/1.73 m2) had a HR of 1.45 (1.65) for
CVD. Female patients with UACR 2.5–3.4 mg/mmol
and eGFR 60–89 ml/min/1.73 m2 (<60 ml/min/1.73 m2)
had a HR of 2.03 (2.17) for all-cause mortality. The
optimal eGFR and UACR for preventing CVD, all-cause
mortality and composite of CVD and all-cause mortality
was ≥90 ml/min/1.73 m2 for eGFR and <1 mg/mmol for
UACR. The interaction effect between eGFR and UACR
for each outcome event was statistically significant. The
risk of developing CVD, all-cause mortality and composite
of CVD and all-cause mortality increased significantly in
other combinations of eGFR and UACR.
Discussion
This is the first study to examine in details the kidney
function, in terms of eGFR and albuminuria, and its as-
sociation with CVD and mortality in Chinese patients
with T2DM at the primary care setting by stratifying pa-
tients into different categories based on different levels
of eGFR and UACR. The risks of CVD, all-cause mortal-
ity, and the composite of the two dropped exponentially
with increasing eGFR. The number of patients with
CKD stage 5 and 4 was very small and hence they were
not separately categorized out during analysis. Patients
with CKD Stage 2 were shown to have a significant
increase in cardiovascular risk (HR 1.17), and the risk el-
evated further as CKD stage progressed (HR 4.55 for
CKD Stage 5). Patients with CKD stage 3 were found to
have significant increase in mortality risk (HR 1.70),
which escalated further as CKD stage progressed (HR
9.49 for CKD stage 5). For patients at CKD stage 3, they
had significant increase in risks of CVD (HR 1.63), all-
cause mortality (HR 1.70), and composite of the two
(HR 1.51). In female, even with normal albuminuria, pa-
tients with eGFR < 90 ml/min/1.73 m2 had a significantly
higher risk of CVD than those with eGFR ≥ 90 ml/min/
1.73 m2, but not for all-cause mortality. This pattern was
not prominent in male. This is not in agreement with
another study that suggested a suboptimal eGFR was a
strong predictor for major CVD in diabetic patients with
normoalbuminuria [24]. Such gender difference needs
further exploration.
Hong Kong had launched a local reference framework
for Diabetes Care for Adults in Primary Care Settings
Hong Kong in 2010 in which the cut-offs of microalbu-
minuria and macroalbuminuria were 2.5 mg/mmol and
25 mg/mmol for male, and 3.5 mg/mmol and 35 mg/mmol
for female respectively [18]. Nevertheless, our study showed
the risks of CVD and all-cause mortality were indeed
elevated even in low urine albumin level of 0.5–0.9 mg/
mmo1. This supports the trend of using the terms “moder-
ately increased albuminuria” and “severely increased
albuminuria” (to replace “microalbuminuria” and “macroal-
buminuria”, respectively) [16, 17] as the cardiovascular risk
did not show an all-or-none relationship but a positive lin-
ear relationship with urine albumin level. Male patients
with UACR as low as 0.5–0.9 mg/mmol were already found
to have increased risk for all-cause mortality (HR 1.23),
whereas a male diabetic patient with UACR as low as 1–
1.4 mg/mmol were found to have a significant enhanced
risk for CVD (HR 1.30). Male patients with microalbumi-
nuria (UACR ≥2.5 mg/mmol) had a HR between 1.58 and
1.79 for outcomes of interest. The HR elevated further
(between 2.21 to 3.26) if they developed macroalbuminuria.
A similar pattern was found in female diabetic patients.
The HR of low eGFR and high albuminuria on CVD and
all-cause mortality found in our study were comparable to
other studies [14, 25, 26].
The amount of albumin leak through the glomerulus
is directly linked to the degree of glomerular damage.
The more advanced the glomerular injury, the less
chance to recover to a normal function. UACR generally
runs a positive linear association with CVD, all-cause-
mortality, and a composite of the two. This supports
that patients with microalbuminuria should be screened
and intervened early. The definition of microalbumi-
nuria and macroalbuminuria varies [18, 27], and their
cut-offs are more like the conceptual terms for easy ref-
erence. It is the amount of albumin that leaks and passes
into urine that matters to a clinician. The link of micro-
albuminuria with cardiovascular events may be attrib-
uted to the endothelial dysfunction in diabetic patients
[5]. Presence of albuminuria is sensitive to detecting
CVD as even with a UACR as low as 1–1.4 mg/mmol, a
significantly increased risk of CVD or all-cause mortality
was found in both men and women. Indeed high-normal
albuminuria was also found to be associated with an in-
creased CVD risk [2, 3, 28–31]. The differences of the
cut-offs for micro/macroalbuminuria in male and female
did not show much differences in the outcome as the
linear relationship showed the more albumin in urine,
the higher risk a patient had. Presence of frank albumin-
uria double or triple the CVD and mortality risk in both
male and female diabetic patients. Converting a diabetic
patient with macroalbuminuria back to microalbumi-
nuria halved the risk. Such association between albumin-
uria and cardiovascular or mortality risk was found
similar to that in non-Chinese [1, 26, 32].
Despite that the amount of albumin leaked into urine
may be transient or fluctuant due to many factors such
as fever or exercise [33], urine ACR seems to have more
impact than eGFR on the clinical practice. Firstly, it was
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theoretically reversible and modifiable. Secondly, testing
for albuminuria was considered to be more informative
than testing eGFR alone. After leakage through the
glomerulus, albumin is not only excreted into urine, but
is also reabsorbed by tubules. Hence, presence of albu-
minuria suggests damages in both glomerular and tu-
bules, in contrast to worsening of eGFR where only
glomerulus damage is suggested [34]. Thirdly, UACR
but not serum creatinine was found to have a significant
association with HbA1c in diabetic patients with both
good and poor control of diabetes [35]. UACR was found
to have a significant positive correlation with HbA1c >8%
and < 8%, but serum creatinine was only significantly asso-
ciated in those with HbA1c >8% [35]. UACR was a more
specific marker for diabetic nephropathy and hence a
closer relationship with DM. The analysis had suggested
that “moderately increased albuminuria” over time is an
important risk factor for CVD and early cardiovascular
mortality [1, 5, 6, 36–39]. Nevertheless, various studies
suggested that CKD had an independent association with
cardiovascular events in diabetic patients [39–41].
Albuminuria control appeared to have less significance
in patients with profound renal impairment as regardless
how good the UACR control in patients with decreased
eGFR was, their risk of cardiovascular events and all-
cause mortality remained high. Tighter albuminuria con-
trol in patients with relatively preserved renal function
(higher eGFR) had greater significance and positive im-
pact on the prognosis in terms of cardiovascular risk
and mortality. For patients with renal impairment with
elevated serum creatinine (lower eGFR), the reduction in
the amount of creatinine passed out into urine may
over-estimate the UACR and it was not truly reflective
of the severity of albuminuria. Although the benefit of
screening UACR is comparatively less in patients with
eGFR <60 ml/min/1.73 m2 when compared to patients
with eGFR ≥60 ml/min/1.73 m2, knowing their UACR
can provide clinicians a more complete picture, particu-
larly when the renal impairment of the patient is caused
by comorbidities other than diabetic nephropathy. Our
study showed that UACR based HR could be further
modified according to eGFR levels, with risk progressed
with stage of CKD, and thus a more patient-centred HR
can be assigned to an individual patient base on the
eGFR and UACR level. With the readiness of converting
frank albuminuria to microalbuminuria or even nor-
moalbuminuria, a female diabetic patient with baseline
eGFR <60 ml/min/1.73 m2 could have her HR of CVD
decreased from 3.23 (albuminuria) to 1.99 (microalbumi-
nuria) to further down (normoalbuminuria). Similarly, a
male diabetic patient with baseline eGFR <60 ml/min/
1.73 m2 could have his HR of CVD decreased from 2.71
(albuminuria) to 2.10 (microalbuminuria) to further down
(normoalbuminuria). On the other hand, for patients with
acceptable eGFR and started to develop mildly increased
albuminuria, timely intervention like tight control of DM
and the use of angiotensin-converting-enzyme inhibitors
(ACEI) or angiotensin receptor blockers (ARB) can
prevent or postpone the progression to moderately or se-
verely increased albuminuria and the subsequent develop-
ment of diabetic nephropathy, which in turn helps to
maintain a satisfactory eGFR level. Controlling the UACR
can also delay the rise of HR towards cardiovascular
events and all-cause mortality, not to mention the renal
complications which are not the focus of this article.
Strengths and limitations of this study
One of the strengths of this study was that the sample
size was large enough to represent the Chinese diabetic
population in Hong Kong. In addition, relevant baseline
covariates such as laboratory results, disease characteris-
tics and treatment modalities were accessed through the
HA’s computerised administrative database which pro-
vided reliable results. Furthermore, multiple imputations
were used to handle missing data to overcome bias in
the results.
On the other hand, several limitations were identified.
Firstly, the analysis did not consider some lifestyle inter-
ventions such as regular exercise and diet modification,
which may be potential contributors to CVD risk. How-
ever, baseline covariates such as duration of T2DM,
BMI, WHR, HbA1c, BP, and lipid, in some sense, can re-
flect the intensity of disease severity and lifestyle modifi-
cation. Secondly, a positive relationship between eGFR/
UACR and risks of CVD and all-cause mortality was
identified. However, this pattern of association may not
be guaranteed in other Chinese populations and is sub-
jected to temporal changes and modifications. Thirdly,
the incidence of outcome events was dependent on the
clinical diagnosis coding by ICPC-2 and ICD-9-CM
codes and documentation in the database, which may
subject to misclassification bias. Fourthly, although all
the laboratories within the HA were certified, there may
be possibilities of between laboratory drift regarding the
results obtained from different laboratories within the HA
across the whole territory. Lastly, the long-term effects of
eGFR/UACR on risk of CVD and all-cause mortality are
yet to be confirmed. Further longitudinal studies with a
minimum follow-up period of 10 years will provide more
evidence on the long-term association between eGFR/
UACR and incidence of CVD and mortality.
Conclusions
Risks of CVD events and all-cause mortality increased ex-
ponentially with eGFR drop, while UACR showed positive
predictive linear relationships, and the risks started even
in Chinese T2DM patients with high-normal albuminuria.
UACR-based HR was further modified according to the
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eGFR levels, with risk progressed with CKD stage. Com-
bining eGFR and UACR level was more accurate in pre-
dicting risk of CVD and all-cause mortality. Serum
creatinine (eGFR) and urinary ACR should be regularly
monitored in diabetic patients. Early intervention to halt
or even reverse the progression reduces the risk of CVD
and all-cause mortality. The findings call for more aggres-
sive screening and intervention of microalbuminuria in
diabetic patients.
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